Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Innovate Biopharmaceuticals Inc (INNT) USD0.001

Sell:$0.75 Buy:$0.80 Change: $0.0171 (2.21%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Change: $0.0171 (2.21%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Change: $0.0171 (2.21%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Innovate Biopharmaceuticals, Inc., formerly Monster Digital, Inc., is a clinical stage biotechnology company. The Company is focused on developing novel autoimmune and inflammation therapeutic drugs. Its lead drug candidate, larazotide acetate (INN-202) is a tight junction regulator. Its other products include INN-108 and INN-329 (Secretin). The Company’s INN-108 is a novel small molecule comprised of two active parts with anti- inflammatory and immunodulatory properties coupled through an azo bond. The Company is developing INN-108 as a therapeutic for Ulcerative Colitis (UC). Its Secretin stimulated magnetic resonance cholangiopancreatography (MRCP) is a ionizing, radiation-free assessment of the pancreaticobiliary system. The Company has completed a phase II b clinical trial for celiac disease for INN-202. It is developing INN-108 in a phase II trial for inflammatory bowel disorders, mild to moderate UC and a Gastrointestinal (GI) orphan disease.

Contact details

8480 Honeycutt Rd Ste 120
United States
+1 (919) 2751933

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$26.77 million
Shares in issue:
35.88 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Sandeep Laumas
    Executive Chairman of the Board, Chief Executive Officer
  • Jay Madan
    President, Chief Business Officer, Director
  • Edward Sitar
    Chief Financial Officer, Principal Accounting Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.